TNFRSF4 and cancer: The ability of OX40 agonists to regulate immune responses, as well as the expression of OX40 on CD4 and CD8 lymphocytes from the tumors and tumor-draining lymph nodes in mice and humans (38, 40, 48), led investigators to examine OX40 manipulation as a treatment for cancer patients.